Moscow’s pharmaceutical enterprises increased production of vaccines and serums by 1.5 times in 2025 compared with 2024, said Anatoly Garbuzov, head of the city’s Department of Investment and Industrial Policy. Total output of drugs and materials for medical and veterinary use rose by 10.2%, he added.
More than 300 pharmaceutical and medical industry enterprises currently operate in Moscow, employing around 30,000 people, Garbuzov said. The capital’s plants produce a wide range of drugs, including medicines for cancer and cardiovascular diseases, antibiotics, painkillers and vaccines.
Drugmaker R-Pharm made a significant contribution to the development of vaccine production, having participated in manufacturing the Sputnik V vaccine during the pandemic. This helped strengthen the capital’s pharmaceutical potential and scale up the output of domestic immunobiological drugs.
Meanwhile, Vetbiochim opened a production facility for immunobiological drugs for farm animals in 2023 at the Pechatniki site of the Technopolis Moscow special economic zone. Over three years, the company has expanded its range to more than 40 proprietary drugs and over 50 diagnostic kits for veterinary use.
Earlier, in February 2026, Moscow mayor Sergei Sobyanin told President Vladimir Putin that the capital aims to become Russia’s top region by pharmaceutical revenue within the next four to five years. Moscow currently ranks second, but the mayor said the city has all the necessary groundwork for a leap forward — including an entire cluster of pharmaceutical enterprises and plans to bring new innovative production facilities online.
